-+ 0.00%
-+ 0.00%
-+ 0.00%

B of A Securities Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $58

Benzinga·01/02/2026 17:08:32
語音播報
B of A Securities analyst Tazeen Ahmad maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and lowers the price target from $72 to $58.